Does the publication of the COURAGE trial reduce the volume of percutaneous coronary interventions in patients with stable angina?
The publication of the COURAGE trial was associated with a 17% decline in PCI volume for stable coronary disease in the US, demonstrating that comparative effectiveness research can influence real-world practice patterns.
OBJECTIVE: To describe trends in the use of percutaneous coronary intervention (PCI) following the COURAGE trial, which found that medical therapy is as effective as PCI for patients with stable angina. DATA SOURCES: We used the National Hospital Discharge Survey; inpatient and outpatient discharge data from Florida, Maryland, and New Jersey; and the English Hospital Episode Statistics database. STUDY DESIGN: We report trends in PCI volume by diagnosis (stable angina vs. unstable angina or AMI) before and after publication of the COURAGE trial. PRINCIPAL FINDINGS: The number of PCIs in patients without a diagnosis of AMI or unstable angina in Florida, Maryland, and New Jersey declined from 48,000 in 2006 to 40,000 in 2008 (-17 percent). There was no change in the number of PCIs in patients with a diagnosis of AMI. We observed similar patterns in U.S. community hospitals. PCI volume did not decline in England. CONCLUSIONS: PCI volume declined after publication of the COURAGE trial. The experience of the COURAGE trial suggests that comparative effectiveness research can lead to cost-saving changes in medical practice patterns. However, there are many patients with stable coronary disease who continue to receive PCI post-COURAGE.
Howard et al. (2013) studied this question.